PBF-680
Sponsors
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Palobiofarma SL
Conditions
Asthma
Phase 1
First-in-human Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers
CompletedNCT01845181
Start: 2013-04-30End: 2013-09-30Updated: 2016-03-08
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 After Multiple Oral Doses
CompletedNCT02208973
Start: 2014-05-31End: 2014-12-31Updated: 2016-03-08
Phase 2
A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.
CompletedNCT02635945
Start: 2016-04-30End: 2019-11-30Updated: 2020-06-30
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients
CompletedNCT03774290
Start: 2018-06-01End: 2020-03-16Updated: 2020-09-25